



JAGSONPAL

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office: T-2110, Shantpur Jat, New Delhi-110 049 (INDIA)
 Fax: 0091-11-26498341-26494708 Phone: 0091-11-26494519-24
 E-mail: admin@jagsonpal.com

Unaudited Financial Results for the Quarter ended 30.09.2010

Particulars	(Rs. in lacs)				
	Quarter ended 30.09.2010 Unaudited	Quarter ended 30.09.2009 Unaudited	6 Months ended 30.09.2010 Unaudited	6 Months ended 30.09.2009 Unaudited	12 Months ended 31.03.2010 Audited
1(a) Net sales/Income from Operations	4583.54	3441.08	8700.58	6771.20	13859.34
1(b) Other Operating Income					
Total	4583.54	3441.08	8700.58	6771.20	13859.34
2 Expenditure					
a (Inc./Dec. in Stock in trade and work in progress)	647.94	-605.44	796.49	-729.13	-1042.09
b. Consumption of Raw Materials	1173.69	1905.45	3126.52	3480.54	7219.40
c. Purchase of traded goods	439.40	920.79	566.71	1043.86	1377.92
d. Employees Cost	901.38	609.04	1586.19	1125.28	2378.78
e. Depreciation	58.09	60.05	115.11	99.83	206.50
f. Other Expenditure	881.43	582.72	1587.80	1182.11	2458.50
g. Total	4095.93	3162.67	7778.82	6205.69	12598.01
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	487.61	278.46	921.96	565.61	1361.33
4 Other Income	0.00	0.00	0.00	0.00	36.30
5 Profit before Int. & Exceptional Items (3+4)	487.61	278.46	921.96	565.61	1397.63
6 Interest	110.81	70.87	185.32	167.87	349.62
7 Profit After Interest but before Exceptional items (5 - 6)	377.00	207.59	736.63	397.74	1050.01
8 Exceptional Items					
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7 +8)	377.00	207.59	736.63	397.74	1050.01
10 Tax expense	100.00	40.00	135.00	80.00	125.81
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	277.00	167.59	600.63	317.74	924.20
12 Extraordinary Items (net of tax expense)					
13 Net Profit (+)/ Loss (-) for the period (11-12)	277.00	167.59	600.63	317.74	924.20
14 Paid up Eq. Sh. Cap. (Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr. Earnings Per Share (EPS):					6049.30
a. Basic & diluted EPS before extraordinary items for the period.	1.06	0.64	2.29	1.21	3.53
b. Basic & diluted EPS after extraordinary items for the period.	1.06	0.64	2.29	1.21	3.53
17 Public shareholding :					
- Number of shares	8962360	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding					
a. Pledged / Encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
b. Non - encumbered					
- Number of shares	17235640	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%

Notes

- The Financial Results for the Quarter ended 30.9.2010 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 13-11-2010
- No complaints were pending at the beginning/end of the quarter ended 30.9.2010. However 38 requests for change of address/dividend revalidation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.



By Order of the Board
 For Jagsonpal Pharmaceuticals Limited

Jagmohan Singh Kochhar
 Chairman

Place : New Delhi
 Date : 13.11.2010